Mean (SD) peak expiratory flow rate (PEFR) in patients receiving additional or not receiving additional medications during the study*
| Time (min) | |||||
|---|---|---|---|---|---|
| 0 | 15 | 60 | 75 | 120 | |
| *Group A: nebulised magnesium sulphate + salbutamol; group B: salbutamol alone. | |||||
| PEFR in patients receiving no additional medications | |||||
| Group A (n = 27) | 134.1 (39.4) | 160.0 (34.1) | 198.5 (28.8) | 235.9 (29.0) | 273.0 (31.4) |
| Group B (n = 27) | 120.7 (35.7) | 147.1 (36.7) | 188.6 (32.4) | 225.4 (32.2) | 269.6 (33.9) |
| p value (group A v B) | 0.193 | 0.184 | 0.235 | 0.207 | 0.708 |
| PEFR in patients receiving additional medications | |||||
| Group A (n = 23) | 100.4 (36.2) | 122.6 (37.8) | 141.7 (38.1) | 166.5 (44.2) | 196.5 (51.0) |
| Group B (n = 23) | 100.0 (49.8) | 115.5 (48.9) | 142.3 (66.0) | 173.2 (57.8) | 193.6 (63.4) |
| p value (group A v B) | 0.973 | 0.585 | 0.974 | 0.665 | 0.867 |